NSRX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

NSRX ▲ +23.19% at T+20d

NEUTRAL call ✓ call won +23.19% · α vs SPY +15.33% · entry $2.76 → $3.40

Next anchor: T+60d in 9d

Currently $2.88 · +4.35% from $2.76 entry

Entry anchored
Mar 24, 03:59 PM ET
via Databento tick

T+1d

-13.04%

call -13.04% · α -11.27%

$2.40

settled 3mo ago

T+5d

-7.61%

call -7.61% · α -7.37%

$2.55

settled 2mo ago

T+20d

+23.19%

call +23.19% · α +15.33%

$3.40

settled 7w ago

T+60d

—

call — · α —

—

in 9d

Price Chart

Loading chart...

Executive Summary

Nasus Pharma released its 2025 annual results and provided a business update, highlighting positive Phase 2 data for its intranasal epinephrine candidate NS002, a strengthened cash position of $4.3 million following its IPO and a $15 million private placement, and plans to initiate a pivotal study for NS002 in Q4 2026. The company also advanced its early-stage pipeline, though it reported a widening net loss of $5.9 million in 2025.

Actionable Insight

The positive Phase 2 data and extended cash runway support near-term clinical execution, but profitability remains distant. Traders should monitor progress toward the NS002 pivotal trial initiation in Q4 2026 and any regulatory feedback. The $15 million financing significantly de-risks the near-term path but adds potential dilution concerns if future offerings are needed.

Key Facts

Positive Phase 2 results for NS002 showed statistically significant improvements in early epinephrine absorption compared to EpiPen®.
Pivotal study for NS002 planned for Q4 2026, with readout expected Q1 2027.
Cash, cash equivalents, and marketable securities totaled $4.3 million as of December 31, 2025, up from $0.3 million in 2024.
Company secured $15 million in private placement in February 2026, extending cash runway into Q2 2027.
Net loss increased to $5.9 million in 2025 from $1.5 million in 2024, driven by higher R&D and G&A expenses.
First-in-human studies for NS003 and NS004 expected in second half of 2026.

Financial Impact

Cash position increased by $4 million YoY; $15 million follow-on financing secured. Net loss widened by $4.4 million. R&D and G&A expenses rose significantly due to clinical development and public company costs.

cashnet lossR&D expensesG&A expenses

Risk Factors

Clinical development risk: Pivotal trial for NS002 may not replicate Phase 2 results.
Dilution risk: Future capital raises may be necessary beyond Q2 2027, impacting shareholders.
Competition: EpiPen® and other epinephrine auto-injectors dominate the market.

Market Snapshot

Exchange

NYSE

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3262206

7 reports for NSRX

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +53.26%Mar 2, 2026

Filters

Reports for NSRX — sortable, filterable
	Type				Now
Apr 1, 2026 10w ago	EFFECT BEARISH ★ 6/10	$2.55 $2.56	▼ −0.39%	▲ +9.33%	$2.88 (−12.94%)
Mar 28, 2026 11w ago	3 NEUTRAL ★ 2/10	$2.01 $2.91	▲ +44.78%	▲ +32.18%	$2.88 (+43.28%)
Mar 28, 2026 11w ago	3 NEUTRAL ★ 3/10	$2.01 $2.91	▲ +44.78%	▲ +32.18%	$2.88 (+43.28%)
Mar 25, 2026 11w ago	Press Release MIXED ★ 6/10	$2.76 $3.40	▲ +23.19%	▲ +15.33%	$2.88 (+4.35%)
Mar 16, 2026 12w ago	Press Release BULLISH ★ 8/10	$3.10 $2.25	▼ −27.42%	▼ −31.20%	$2.88 (−7.10%)
Mar 16, 2026 12w ago	EFFECT NEUTRAL ★ 5/10	$3.10 $2.25	▼ −27.42%	▼ −31.20%	$2.88 (−7.10%)
Mar 2, 2026 14w ago	F-1 BEARISH ★ 6/10	$4.75 $2.22	▲ +53.26%	▲ +48.86%	$2.88 (+39.37%)

US Market Status

Market Closed — Opens Mon (49h 42m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access